Insmed Incorporated
INSMHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeInsmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company carries a $22.48B market cap, placing it firmly in the large-cap category. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Market Cap
$22.48B
Beta
0.89
P/E (TTM)
—
P/E (Fwd)
256.73
EPS (TTM)
$-5.76
EPS (Fwd)
$0.40
ROE
-294.5%
ROA
-31.1%
Cash
$1.22B
Total Debt
$742.5M
Free CF
-$606.2M
52W Change
40.8%
Annual Financials
Cash vs Debt
Insmed Incorporated holds $1.22B in cash against $742.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$606.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -294.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $245.4M (2022) to $606.4M (2025), reflecting a 147% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Insmed Incorporated's trajectory.